Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label safety study of Mim8 prophylaxis in haemophilia A patients switching from emicizumab
KCT0008605Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of denecimig in hemophilia A, sponsored by Novo Nordisk. Started Aug 2023; status: completed.
02
Drugs
denecimig
03
Conditions
hemophilia A
Beyond the preview
Go deeper on KCT0008605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008605.